The ImmunoGenesis team presented important preclinical data for the STING agonist, IMGS-203 at the recent Society for Immunotherapy of Cancer conference #SITC24 in our hometown of Houston, TX. This data is a critical piece of the IND-enabling activities the company is conducting to bring this treatment to patients for the treatment of cold tumors.
ImmunoGenesis, Inc.
Biotechnology Research
Houston, Texas 1,018 followers
Re-envisioning cold tumor treatment. Our deliberate drug development strategy targets mechanisms of immune resistance.
About us
ImmunoGenesis is a clinical-stage immuno-oncology biopharmaceutical company re-envisioning the treatment of "cold" tumors, particularly of immune-excluded tumors. Immune-excluded tumors, which account for more than half of all cancers, are characterized by having mechanisms of resistance that suppress the immune response; this subgroup is resistant to current immunotherapies. ImmunoGenesis is creating therapies based on the pathology of these immune-excluded tumors that are rationally designed to overcome immune exclusion and thereby drive an effective immune response. We look at cold, immune-excluded tumors through a new lens, re-envisioning treatment with a deliberate drug development strategy based in cold tumor pathology.
- Website
-
https://www.immunogenesis.com
External link for ImmunoGenesis, Inc.
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- Houston, Texas
- Type
- Privately Held
- Founded
- 2019
Locations
-
Primary
Get directions
2450 Holcombe Blvd
Suite J
Houston, Texas 77021, US
Employees at ImmunoGenesis, Inc.
Updates
-
Come see our CEO, James Barlow, talk about how ImmunoGenesis is transforming immuno-oncology at the Life Sciences Future conference being conducted by Life Sciences PA. @life sciences Pennsylvania Life Sciences Future - It's Here! Tickets in King of Prussia, PA, United States (ticketleap.com)
-
-
Join our CEO who will be presenting ImmunoGenesis, Inc at the Keiretsu Forum Northwest and Rockies, July 2024 Roadshow. Register as a guest and get free access to all the events. Register here - https://lnkd.in/etKwj5tv
-
-
ImmunoGenesis to participate at the Annual Keiretsu Forum Midwest 2 Northeast Life Sciences Innovation Summit in Chicago on March 21st. We are happy to announce that ImmunoGenesis will be participating at the upcoming Keiretsu Forum Midwest 2 Northeast Life Sciences Innovation Summit in Chicago on March 21st. At the Summit we will be presenting our latest technology and take part in panel discussions around the future of Therapeutics as well as the impact of A.I on the industry as we steer ahead. I hope you can join us! Our latest news at ImmunoGenesis: ImmunoGenesis is seeking to transform immuno-oncology as it develops two clinical-stage assets. The company's lead drug, IMGS-001, is a dual-specific PD-L1/PD-L2 inhibitor that combines the ability to kill immunosuppressive stroma with optimal PD-1 pathway blockade. This drug has been engineered with the potential to drive robust efficacy in immune-excluded tumors (majority of cancers), where current immunotherapies are not effective. A phase 1a/1b clinical trial for IMGS-001 has already been initiated. The company's second clinical asset, IMGS-101, is a hypoxia reversal agent that synergizes with checkpoint inhibitors. A phase 1/2 trial for this drug in combination with PD-1 and CTLA-4 inhibition across prostate, pancreatic and head and neck cancers will be initiated shortly.
-